Currently limited data are available on their efficacy in ALL; however, several studies regarding the use of anti-PD1 (NCT02819804, NCT02767934) and anti-CTLA4 (NCT02879695, NCT01919619) antibodies in ALL are ongoing. The gene discussed is CTLA4; the disease is acute lymphoblastic leukemia.